The world’s pharmaceutical industry is dominated by the American and European markets. According to Forbes’ list of World’s 10 Most Reputable Pharmaceutical Companies in 2017, almost all of the top 10 biggest pharma companies are all located in these two regions.
Although other regions like China and India have seen growth in recent years when it comes to the life science markets due to potent capital opportunities and an expanding demand for products and devices, the US and Europe remain on the top of the line for pharmaceutical consumption and development.
Healthy and transparent systems allow for public companies to bring their products to the market after proper vetting. Patents allow the protection of novel candidates and treatments against serious diseases. With that in mind, here the Investing News Network (INN) breaks down the two top pharmaceutical regions in more detail.
Top pharmaceutical regions: United States
The US dominates the pharmaceutical market, both in consumption and development. In 2016 medicine spending in the US reached was projected to reach $450 billion total.
In 2017 through the Center for Drug Evaluation and Research (CDER) the US Food and Drug Administration approved a total of 46 new drugs into the market. Among them included treatments for certain types of ocular hypertension, mantle cell lymphoma, and metastatic breast cancers.
The US is the world’s leader in research and development. In 2013, the industry saw over over 6,000 sponsored clinical trials in the US, involving 1.1 million volunteer participants in this endeavour.
According to a study by the JAMA Network in 2017 showed the approximate cost to discover a single cancer drug was upwards of $648 million, which is lower than previous estimates, but still high.
US biopharmaceutical companies directly provide jobs to more than 810,000 Americans and indirectly support the jobs of 3.5 million Americans. Overall, the economic output of this work was valued at approximately US$1.2 trillion in 2014, making it one of the most important sectors of the American economy.
A strong intellectual property system, which rewards innovation and improvement of current treatments ensures a supportive pharmaceutical market for public companies, according to the report from the International Trade Administration. “The United States attracts the majority of global venture capital investments in start-up biopharmaceutical enterprises,” the report stated.
Top pharmaceutical regions: Europe
The rest of the top 10 pharmaceutical companies on Forbes for the top pharmaceutical regions include enterprises from Switzerland, France, and the UK, including some names like Novartis (NYSE:NVS) and Sanofi (NYSE:SNY).
Production of pharmaceutical products reached €202,000 million in 2016 according to the European Federation of Pharmaceutical Industries and Association. This, in turn, boosted the continent to account for 17.5 percent of the total pharmaceutical sales in the world–just behind the US which represents 64.7 percent of sales of new medicines launched during 2010 and 2015.
This is an updated version of an article first published in 2015 on the Investing News Network, with the latest update done by Gabrielle Lakusta.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.